[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pediatric-all\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pediatric-all":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,44,83,110,138,166,196,220,246,271,297,319,344,365,388,415,446,476,496,520,552,576,602,627,655],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100652899","nurture-by-nature-feasibility-study-100652899",false,"NCT07780123","Nurture by Nature Feasibility Study","A Feasibility Study of a Cluster Randomized Controlled Trial of a Nature-based Intervention Enhancing Mental and Physical Well-being Among Kindergarten Children From Deprived Areas: Nurture by Nature","Inclusion Criteria:\n\nA kindergarten cluster will be eligible for study participation if the cluster meets the following criteria:\n\n1. The kindergarten should geographically be located within or near by a social housing area or serve children from such an area.\n2. At least 11 children in the cluster, each:\n\n   1. aged 4-7 years due to the primary outcome cutoff age, and\n   2. have a parent who is able to understand and communicate in Danish, and\n   3. have consented to participate\n\nInclusion criteria of children and parents:\n\nA child and parent will be eligible for study participation if they meet the following criteria:\n\n1. the child is aged 4-7 years due to the primary outcome cutoff age, and\n2. the parent is able to understand and communicate in Danish, and\n3. have consented to participate\n\nInclusion criteria of kindergarten personnel:\n\nKindergarten personnel will be eligible for study participation if they meet the following criteria:\n\n1. if they have \\>80% of their working hours in the eligible kindergarten cluster\n2. have consented to participate\n\nExclusion Criteria:\n\nA kindergarten cluster will not be eligible for the study if the cluster meets any of the following criteria:\n\n1. the kindergarten is currently spending \\> two days per week in nature (green outdoor),\n2. the kindergarten is already using the ''Green Sprouts'' program,\n3. the kindergarten is exclusively for children with special needs All exclusion criteria are at cluster level. There are no individual exclusion criteria.",true,"ALL","4 Years",{"count":21,"type":22},127,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this feasibility cluster randomized trial is to determine whether a future large pragmatic cluster randomized controlled trial can be conducted to evaluate the effects of a nature-based intervention on children's mental and physical health. The intervention will be delivered in preschools located in or near public housing areas and compared with usual activities in similar preschools.\n\nThe main questions it aims to answer are:\n\n* Are parents willing to participate in follow-up assessment using the Strengths and Dif-ficulties Questionnaire (SDQ)?\n* Can participants be successfully recruited, and can the nature-based intervention be delivered as intended?\n* Is it possible to gather data on children's motor development, physical activity, sleep, absenteeism, and stress, and on stress and absenteeism among educators and parents?\n* Is the intervention safe and acceptable for children, parents, and educators?\n\nResearchers will compare a 14-week nature-based intervention with usual preschool activities.\n\nThe nature-based intervention is based on the Danish Outdoor Council's Green Sprouts (\"Grønne Spirer\") programme and focuses on using nature for play and learning. The intervention is being developed together with educators and children and includes nature-based activities designed to support motor development, physical activity, and positive interactions between children.\n\nParticipants will:\n\n* Take part in either the nature-based intervention or usual preschool activities.\n* Complete questionnaires about child well-being, quality of life, and parental stress.\n* Participate in assessments of fine and gross motor skills.\n* Wear an activity monitor to measure physical activity and sleep.\n* Provide hair samples for measurement of stress-related hormones.\n* Take part in interviews and observations.\n\nThe study will include approximately 56 children aged 4 to 6 years, their parents, and approx-imately 15 educators.\n\nThe results will help determine whether the intervention can be implemented in preschools as currently designed and will inform the planning of a future large cluster-randomized controlled trial. No major risks are expected. Participants may experience minor discomfort when a small hair sample is collected for stress measurement.",[28,29,30],"Nature, Human","Pediatric ALL","Well-Being, Psychological","NOT_YET_RECRUITING","2026-08-18",{"date":34,"type":35},"2026-08-21","ACTUAL",{"date":37,"type":22},"2026-10-01",{"date":39,"type":22},"2027-12-31",{"name":41,"class":42},"Ina Olmer Specht","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":58,"conditions":59,"keywords":71,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100652162","phase-1-a-study-of-sonrotoclax-bgb-11417-in-children-with-relapsed-or-refractory-acute-myeloid-leukemia-and-b-cell-acute-lymphoblastic-leukemia-100652162","NCT07770698","A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia","A Phase 1\u002F2a, Open-Label, Dose Finding and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sonrotoclax (BGB-11417) in Combination With Other Agents in Pediatric Patients Aged 6 Months to 17 Years, With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia","Key Inclusion Criteria\n\nParticipants must meet all of the following criteria to be eligible for participation:\n\n1. Have a performance status of Lansky ≥50 for participants ≤16 years of age or Karnofsky ≥50 for participants \\>16 years of age.\n2. Have adequate renal function, defined as an estimated or measured glomerular filtration rate (GFR) ≥60 mL\u002Fmin.\n3. Have adequate hepatic function, defined as:\n\n   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C2.5 × the institutional upper limit of normal (ULN)\n   * Total bilirubin ≤1.5 × the institutional ULN.\n4. Have minimum cardiac function as defined in the study protocol.\n\nAcute Myeloid Leukemia (AML)-Specific Inclusion Criteria\n\n1. Have a histologically confirmed diagnosis of acute myeloid leukemia (AML) that is relapsed or refractory (R\u002FR) after ≥2 prior lines of systemic therapy.\n2. Have ≥5% blasts in a bone marrow aspirate or biopsy sample, as assessed by morphology. Participants with extramedullary, non-central nervous system (CNS) disease are eligible.\n\nB-Cell Precursor Acute Lymphoblastic Leukemia (ALL)-Specific Inclusion Criteria\n\n1. Have a histologically confirmed diagnosis of B-cell precursor acute lymphoblastic leukemia (ALL) that is R\u002FR after ≥2 prior lines of systemic therapy, including at least 1 line of blinatumomab-based therapy.\n2. Have ≥5% blasts in a bone marrow aspirate or biopsy sample, as assessed by morphology.\n3. Have leukemic blasts expressing cluster of differentiation 22 (CD22) on the cell surface, as assessed by flow cytometry of a bone marrow aspirate.\n\nKey Exclusion Criteria\n\nParticipants will be excluded from participation if any of the following apply:\n\n1. Have central nervous system (CNS) 2 or CNS 3 disease at screening.\n2. Have toxicity from prior anticancer therapy that has not recovered to ≤Grade 1, as defined by the applicable toxicity grading criteria.\n3. Have a history of prior allogeneic stem cell transplantation \\\u003C90 days from enrollment or if if ≥ 90 days from enrollment, with active graft-versus-host disease (GVHD), or requiring immunosuppressive drugs for treatment of GVHD, or have taken calcineurin inhibitors within 4 weeks prior to consent.\n\nAML-Specific Exclusion Criteria\n\n1. Have a diagnosis of acute promyelocytic leukemia (APL) or juvenile myelomonocytic leukemia (JMML).\n2. Have AML with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), as determined by local assessment.\n\nALL-Specific Exclusion Criteria\n\n1. Have Philadelphia chromosome-positive (Ph+) ALL with a breakpoint cluster region::Abelson murine leukemia viral oncogene homolog 1 (BCR::ABL1) fusion.\n2. Have received prior therapy with a B-cell lymphoma 2 (BCL-2) inhibitor.\n\nNote: Other eligibility criteria may apply.","6 Months","17 Years",{"count":54,"type":22},30,[56,57],"PHASE1","PHASE2","The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment or has not responded to treatment. The study will also learn how the body processes sonrotoclax when it is given with other medicines. The main questions it aims to answer are:\n\n* Is sonrotoclax safe and well tolerated when given with other anti-cancer medicines?\n* How does the body absorb, process, and remove sonrotoclax?\n* Does treatment with sonrotoclax, in combination with other medicines, help reduce or eliminate leukemia?\n\nResearchers will give sonrotoclax together with other anti-cancer medicines to participants with relapsed or refractory AML or ALL. Participants will:\n\n* Take sonrotoclax in combination with other anti-cancer medicines\n* Have regular clinic visits for physical exams, blood tests, heart monitoring, and other safety assessments.\n* Provide blood samples to measure how the body processes sonrotoclax.\n* Have tests to evaluate how their leukemia responds to treatment.\n* Continue treatment as long as it is helping and side effects remain manageable, according to the study plan.",[60,61,62,63,64,29,65,66,67,68,69,70],"Relapsed Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia","B-cell Acute Lymphoblastic Leukemia","Pediatric Cancer","Pediatric ALL, Relapsed","Pediatric ALL, B Cell","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Pediatric AML","R\u002FR AML","R\u002FR B-cell ALL",[70,69,68,67,66,65,29,64,63,60,61,72,73],"Sonrotoclax","Pediatric","2026-08-17",{"date":32,"type":35},{"date":77,"type":22},"2026-10",{"date":79,"type":22},"2031-09",{"name":81,"class":82},"BeOne Medicines","INDUSTRY",{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":18,"minAge":90,"maxAge":52,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100537204","safety-study-to-evaluate-the-occurrence-of-efad-in-pediatric-patients-with-pnac-who-require-more-than-eight-weeks-of-omegaven-treatment-100537204","NCT06274788","Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment","Title: A Single-arm, Open-label, Prospective, Multicenter Safety Study to Evaluate the Occurrence of Essential Fatty Acid Deficiency (EFAD) in Pediatric Patients With Parenteral Nutrition-associated Cholestasis (PNAC) Who Require More Than Eight Weeks of Omegaven Treatment","Inclusion Criteria:\n\n1. Patient's parent(s) or legal guardian(s) has provided a signed and dated Informed Consent Form (ICF).\n2. Pediatric patient (\\\u003C18 years) has been diagnosed with PNAC, defined as direct or conjugated bilirubin (DBil) ≥ 2.0 mg\u002FdL with no other known cause of liver dysfunction at the time of enrollment and is expected to require Omegaven treatment for at least eight weeks.\n3. Patient has oral or enteral feeding intolerance or at least one gastrointestinal disorder requiring PN.\n\nExclusion Criteria:\n\n1. Patient has received Omegaven within four weeks before inclusion in the study\n2. Patient has any other known cause of chronic liver disease such as hepatitis C, cystic fibrosis, biliary atresia, alpha-1-antitrypsin deficiency, passive hepatic congestion due to heart failure, etc.\n3. Patient has known cirrhosis (liver biopsy is not required under this protocol).\n4. Patient has been previously diagnosed with, or has prior evidence of, portal vein thrombosis.\n5. Patient has previously received a liver-only or liver-inclusive transplant.\n6. Patient has hemodynamic instability due to any major cardiac anomaly.\n7. Patient has a major life-threatening disease (e.g., sepsis requiring high-dose vasopressors, acute respiratory distress syndrome, veno-occlusive disease, cancer).\n8. Patient has multi-organ failure, septic shock, hypotension requiring pressor therapy, persistent pulmonary hypertension requiring inhaled nitric oxides, or requires extracorporeal membrane oxygenation (ECMO) or similar intervention.\n9. Patient has renal failure and requires renal replacement therapy.\n10. Patient has a severe hemorrhagic disorder.\n11. Patient has severe hyperlipidemia or a severe disorder of lipid metabolism characterized by hypertriglyceridemia (i.e., serum triglyceride level \\> 1,000 mg\u002FdL).\n12. Patient has a record of EFAD before inclusion in the study\n13. Patient has been diagnosed with or is suspected to have an inborn error of metabolism.\n14. Patient has a known hypersensitivity to fish or egg protein or to any of the active ingredients or excipients of Omegaven.\n15. Patient is subject to treatment limitation.\n16. Patient is enrolled in any other study with an investigational medicinal product during the course of the current study.","1 Day",{"count":92,"type":22},40,"OBSERVATIONAL","This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population",[96,97,98,29],"Parenteral Nutrition Associated Liver Disease (PNALD)","Essential Fatty Acid Deficiency","Malnutrition","RECRUITING","2026-08-12",{"date":102,"type":35},"2026-08-14",{"date":104,"type":35},"2024-12-15",{"date":106,"type":22},"2028-04-01",{"name":108,"class":82},"Fresenius Kabi",10,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":52,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":43},"100575403","evaluation-of-pediatric-ecart-implementation-100575403","NCT06771830","Evaluation of Pediatric eCART Implementation","A Rapid Diagnostic of Risk in Hospitalized Pediatric Patients to Improve Outcomes Using Machine Learning","Inclusion Criteria (pediatric patients):\n\n* All pediatric patients scored on pediatric eCART (or eligible for scoring on either algorithm in the pre-implementation period) will be screened for study eligibility.\n* Patients eligible for pediatric eCART scoring include pediatric (\\\u003C18 years of age) patients\n* Inpatient locations\n\nExclusion Criteria (pediatric patients):\n\n* Patients who are ineligible for pediatric eCART scoring\n* Neonates and birth encounters will be excluded from the pediatric eCART study\n\nInclusion Criteria (nurse clinicians):\n\n* UW Health nurses who interact with eCART during patient care\n\nExclusion Criteria (nurse clinician):\n\n* UW Health nurses no longer employed at UW Health",{"count":118,"type":22},30000,[25],"This is a study comparing 3 years of retrospective data (pre-implementation) to 2 years of prospective data after the implementation of a pediatric version of Electronic Cardiac Arrest Risk Triage (pediatric eCART), a clinical decision support (CDS) tool that uses electronic health records (EHR) to identify patients with high risk for life threatening outcomes. Up to 30,000 encounters with pediatric patients will be assessed. Acceptability of the pediatric eCART intervention will also be measured from pediatric nurse clinicians.",[29,122],"Sepsis",[124,125,126,127,128],"machine learning","artificial intelligence","clinical decision support","triage","electronic medical records","2026-08-10",{"date":131,"type":35},"2026-08-13",{"date":133,"type":35},"2025-12-01",{"date":135,"type":22},"2027-12",{"name":137,"class":42},"University of Wisconsin, Madison",{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":17,"sex":18,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100523947","multicenter-homevent-home-values-and-experiences-navigation-track-100523947","NCT06102330","Multicenter HomeVENT: Home Values and Experiences Navigation Track","HomeVENT","Inclusion Criteria:\n\n1. English- or Spanish-speaking\n2. Males and females; Age 18 and over.\n3. Parent of a child facing a decision about home ventilation within 30 days. A \"parent\" will be defined as any self-identified primary caregiver (parents, grandparents, etc).\n\n   or Physician of a child whose parents are enrolled in the study; physician must be engaged in the home ventilation decision.\n4. Provision of signed and dated informed consent form (parent) or completion of oral consent (physician)\n5. Stated willingness to comply with all study procedures and availability for the duration of the study\n6. Access to necessary resources if choose to participate via internet or telephone\n\nExclusion Criteria:\n\n1. Excluding children as they cannot be legal decision-makers\n2. Non-English or Non-Spanish speaking parents, as the intervention website\u002F videos are only available in those two languages.","18 Years",{"count":147,"type":22},600,[25],"This is a multicenter study to test a decision-making support process for families and clinicians facing decisions about chronic home ventilation for a child. The investigators hypothesize that the intervention will increase family preparedness for decision-making and will improve clinician-family shared-decision making. Half of families will be assigned to \"usual care\" arm and half to the \"intervention\" arm. Intervention families will view the study website with study staff and will answer questions related to website content. All families will be interviewed and surveyed at 1, 6 and 12 months after enrollment. Each family will designate 1-2 physician involved in the decision about home ventilation; each physician will be interviewed and surveyed at 1 month.",[29,151,152],"Respiratory Insufficiency","Communication",[154,155],"chronic ventilation","decision-making","2026-07-15",{"date":158,"type":35},"2026-07-16",{"date":160,"type":35},"2024-02-06",{"date":162,"type":22},"2030-12",{"name":164,"class":42},"Johns Hopkins University",4,{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":12,"sex":18,"minAge":173,"maxAge":145,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":176,"briefSummary":177,"conditions":178,"keywords":182,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":4},"100572913","hospital-based-continuous-patient-monitoring-system-100572913","NCT06739447","Hospital Based Continuous Patient Monitoring System","Implementing a Hospital-based Continuous Patient Monitoring System Using Consumer Wearable Devices in Ghana","Inclusion Criteria:\n\n* Pediatric patients presenting with traumatic injury\n* Pediatric patients postoperative status after an appendectomy\n\nExclusion Criteria:\n\n* Pediatric patients missing their upper limbs,\n* Pediatric patients who cannot wear a Fitbit on their wrist for known allergies to rubber or those with traumatic or medical conditions that prevent them from being able to comfortably wear a Fitbit on either hand","3 Years",{"count":175,"type":22},250,[25],"In Ghana, and many other low and middle income countries in Africa, manual vital signs monitoring is the prevalent mode of vital signs monitoring because continuous bedside monitors are non-functional. This lack of continuous vital signs monitoring may result in missed opportunities to catch physiologic deterioration.\n\nThe investigators propose to develop a dashboard that is based on the Garmin Venu 3, a consumer wearable device that reliably measures heart rate, SPO2, and respiratory rate, as an alternative to bedside monitors in hospitals in Ghana.",[179,180,29,181],"Trauma","Appendectomy","Vital Signs Monitoring",[183,184,185,186],"Garmin Venu 3","pediatric appendectomy","trauma","vital sign monitoring","2026-06-30",{"date":189,"type":35},"2026-07-02",{"date":191,"type":22},"2026-09-01",{"date":193,"type":22},"2030-01-30",{"name":195,"class":42},"University of Alabama at Birmingham",{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":43},"100430143","phase-1-study-of-cd19-allogeneic-memory-t-cell-therapy-for-relapsedrefractory-cd19-leukemia-100430143","NCT04881240","Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed\u002FRefractory CD19+ Leukemia","A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia","Inclusion Criteria Eligibility Criteria for Donors: Apheresis and Manufacturing\n\n* Age ≥ 18 years old\n* At least single haplotype matched (≥ 3\u002F6) family member\n* HIV negative\n* For females of child bearing age: Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND Not lactating with intent to breastfeed\n* Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance\n\nFor Cohort A only, identified recipient with relapsed and\u002For refractory CD19-positive leukemia\n\nFor Cohort B only, iIdentified recipient with relapsed and\u002For refractory CD19-positive leukemia who is not suitable to receive autologous CD19-CAR T-cell therapy as defined by the following:\n\n* Relapsed and\u002For refractory disease despite prior treatment with autologous CD19- CAR T-cell therapy\n* History of prior autologous leukapheresis failure\n* History of prior autologous CAR T-cell manufacturing failure\n* Unable to undergo autologous leukapheresis in the opinion of the study PI(s): examples may include - patient small size\u002Flow weight, inadequate T-cell counts, rapidly progressive leukemia, clinical status not amenable to apheresis\n\nEligibility Criteria for Patients: Treatment\n\n* Age ≤ 21 years old\n* Relapsed and\u002For refractory CD19-positive leukemia\\*:\n\n  * Refractory disease (defined as any of the following):\n\n    * Primary refractory disease despite at least 2 cycles of an intensive chemotherapy regimen designed to induce remission\n    * Refractory disease despite salvage therapy\n  * Relapsed disease (defined as any of the following):\n\n    * 2nd or greater relapse\n    * Any relapse after allogeneic hematopoietic cell transplantation (HCT)\n    * 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and\u002For unsuitable for HCT\n\nCD19-positivity confirmed within 2 months and after receipt of any CD19-directed therapy\n\n* Patient cohorts:\n\n  * Cohort A: patient has previously received a HCT from the selected CAR T-cell donor\n  * Cohort B - patient has NOT previously received a HCT from the selected CAR T-cell donor.\n* For Cohort B only, not suitable to receive autologous CD19-CAR T-cell therapy as defined above in Criteria: Eligibility Criteria for Donors: Apheresis and Manufacturing\n* Detectable medullary CD19-positive leukemia\n* Estimated life expectancy of ≥ 8 weeks\n* Karnofsky or Lansky performance score ≥ 50\n* No CNS-3 disease or any level of detectable leukemia in CNS with associated neurologic symptoms\n* If history of allogeneic HCT (regardless of donor type), prior to planned CAR T-cell infusion, must meet the following criteria:\n\n  * ≥ 3 months from HCT\n  * have recovered from prior HCT therapy\n  * have no evidence of active GVHD within prior 2 months\n  * have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned CAR T-cell infusion\n* Adequate cardiac function: left ventricular ejection fraction ≥ 40% or shortening fraction ≥ 25% (function may be supported by pharmacologic therapy)\n* EKG without evidence of clinically significant arrhythmia\n* Adequate renal function: creatinine clearance or radioisotope GFR 50 ml\u002Fmin\u002F1.73m2 (GFR 40 ml\u002Fmin\u002F1.73m2 if \\\u003C 2 years of age)\n* Adequate pulmonary function: forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing\n* Total bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age\n* No history of HIV infection\n* No evidence of severe, uncontrolled bacterial, viral or fungal infection\n* Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy\n* For females of child bearing age:\n\n  * Not pregnant with negative serum or urine pregnancy test ≤ 7 days prior to enrollment AND Not lactating with intent to breastfeed\n* If sexually active, agreement to use birth control until 6 months after CAR T-cell infusion\n* No history of hypersensitivity reactions to murine protein-containing products\n* Not receiving systemic steroids therapy exceeding the equivalent of 0.5 mg\u002Fkg\u002Fday of methylprednisolone ≤ 7 days prior to CAR T-cell infusion\n* Not receiving systemic therapy ≤ 14 days prior to CAR T-cell infusion, which will interfere with the activity of the CAR T-cell product in vivo (in the opinion of the study PI(s))\n* Not receiving intrathecal chemotherapy ≤ 7 days prior to CAR T-cell infusion\n\nExclusion Criteria:\n\nNA","21 Years",{"count":205,"type":22},60,[56],"This is a Phase I clinical study evaluating the safety and maximum tolerated dose of a novel CAR T-cell product: allogeneic memory (CD45RA- negative) T-cells expressing a CD19-specific CAR 41BBz (CD19-CAR.CD45RA- negative T-cells) for the treatment of patients ≤ 21 years old with relapsed and\u002F or refractory CD19-positive leukemia.\n\nPrimary Objective\n\nTo determine the maximum tolerated dose (MTD) and characterize the safety profile and dose-limiting toxicities (DLTs) of treatment with allogeneic CD19-CAR.CD45RA-negative T-cells in pediatric, adolescent and young adult patients ≤ 21 years of age, with relapsed and\u002For refractory CD19-positive leukemia.\n\nSecondary Objectives\n\n* To evaluate the anti-leukemic activity of allogeneic CD19-CAR.CD45RA-negative T-cells.\n* To determine rates and severity of graft-versus-host-disease (GVHD) after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells.\n\nExploratory Objectives\n\n* To study the expansion, persistence and phenotype of allogeneic CD19-CAR.CD45RA-negative T-cells.\n* To characterize the cytokine profile in the peripheral blood and CSF after treatment with allogeneic CD19-CAR.CD45RA-negative T-cells.\n* To assess whether allogeneic CD19-CAR.CD45RA-negative T-cells acquire functional versus exhaustion-associated epigenetic programs.\n* To determine immune reconstitution post treatment, and the clonal structure and endogenous repertoire of allogeneic CD19-CAR.CD45RA-negative T-cells and relate inferred specificity to CAR response profiles.\n* To characterize incidence and mechanisms of relapse post-therapy with allogeneic CD19-CAR.CD45RA-negative T-cells.",[209,210,29],"Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia, Refractory","2026-05-20",{"date":213,"type":35},"2026-05-26",{"date":215,"type":35},"2024-02-14",{"date":217,"type":22},"2028-07-01",{"name":219,"class":42},"St. Jude Children's Research Hospital",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":12,"sex":18,"minAge":228,"maxAge":52,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":43},"100589620","multiphase-optimization-strategy-most-for-treating-pediatric-post-traumatic-stress-disorder-ptsd-100589620","NCT06956781","Multiphase Optimization Strategy (MOST) for Treating Pediatric Post-traumatic Stress Disorder (PTSD)","Optimizing Behavioral Health Services Following Pediatric Trauma Exposure","MOST for PTSD","Inclusion Criteria:\n\nA child between the ages of 8-17 exposed to at least one DSM-defined trauma\n\nChild assent for participation\n\nThe participation of a caregiver with custodial rights to provide parental permission\n\nWilling to participate in treatment delivery and respond to surveys\n\nMeet PTSD diagnostic criteria that is the result of exposure to at least one of the identified traumas\n\nAbility to read and understand English\n\nWillingness to be randomized to an experimental condition\n\nPlacement in a stable caregiving environment for two months without an impending transition\n\nChildren currently taking psychotropic medications must have taken the medicine without dose adjustment for two months prior to study entry.\n\nCaregiver or child with a smartphone capable of downloading a freely available software application.\n\nExclusion Criteria:\n\nPsychiatric concerns requiring a higher level of care (e.g. suicidal ideation with intent; current psychotic disorder)\n\nAn intelligence quotient (IQ) \\\u003C 70\n\nCurrently receiving a behavioral health intervention for concerns related to PTSD or pediatric trauma\n\nA participating caregiver who is a perpetrator of any identified trauma (e.g. sexual abuse)\n\nMRI contraindicators (e.g. presence of metal in the body)","8 Years",{"count":230,"type":22},200,[25],"The goal of this clinical trial is to test the extent to which different treatment components work to improve pediatric post-traumatic stress disorder (PTSD). It will also provide evidence for how these components work. The main research questions are:\n\nWhat are the effects of different components used to treat PTSD? What do these components change to produce benefits in PTSD?\n\nResearchers will:\n\nCompare components to a psychological placebo to estimate their effects and measure how they work\n\nExamine how components work alone and in conjunction with other components\n\nParticipants will:\n\nReceive different combinations of components and placebo\n\nAttend weekly treatment sessions\n\nProvide information to evaluate changes in PTSD",[234,179,29],"PTSD",[234,179,73,236],"Multiphase Optimization Strategy","2026-04-07",{"date":239,"type":35},"2026-04-08",{"date":241,"type":35},"2026-03-15",{"date":243,"type":22},"2028-08",{"name":245,"class":42},"University of Rochester",{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":18,"minAge":253,"maxAge":145,"enrollmentInfo":254,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":256,"conditions":257,"keywords":260,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":269,"locationsCount":43},"100541086","exercise-mri-to-evaluate-cardiorespiratory-fitness-in-children-with-heart-disease-100541086","NCT06325280","Exercise MRI to Evaluate Cardiorespiratory Fitness in Children With Heart Disease","Utilizing Exercise Cardiovascular and Skeletal Magnetic Resonance Imaging to Evaluate Factors Associated With Cardiorespiratory Fitness in Children With Acquired and Congenital Heart Disease","Inclusion Criteria:\n\n* 10 - 18 year olds followed at the Stollery Children's Hospital\n* Heart transplant recipients ≥6 months post-transplant\n* Have a moderate-complex congenital heart disease diagnosis\n\nExclusion Criteria:\n\n* Non-English speaking\n* Exercise restricted by the patient's clinical cardiologist\n* Clinical antibody- or cellular-mediated rejection within 3-months of the assessment or during the study period (for HTRs)\n* Previous involvement in a CR or exercise intervention program\n* Previous exercise stress test demonstrating sustained arrhythmias, ST segment elevation or depression greater than 3mm, an inappropriate rise in blood pressure (BP) (\\\u003C20 mmHg) or a systolic BP \\>200 mmHg, or symptoms of chest pain or syncope\n* Resting arterial saturation \\\u003C85% or oxygen requirements\n* Moderate ventricular systolic dysfunction (or worse) at the most recent echocardiogram\n* History of chest pain on exertion; unrepaired\u002Funpalliated CHD\n* Arrhythmias in the last year (including supraventricular tachycardia, ventricular tachycardia, atrioventricular block or history of (Mobitz II or worse))\n* New York Heart Association class II or worse symptoms\n* Active medical inter-current illness limiting ability to participate\n* Cognitive impairment limiting the communication needed for the exercise MRI\n* Research MRI contraindications (e.g. any type of pacemaker), or any orthopedic limitation preventing exercise testing\n* Extracardiac or congenital abnormality limiting the participant's functional ability to exercise\n* Pregnant","10 Years",{"count":255,"type":22},20,"There are many barriers to heart-healthy lifestyles in pediatric patients with acquired and congenital heart disease. Investigators want to further understand how participants heart and skeletal muscles work together during exercise and evaluate the impact on cardiac function. To do this, the investigators will use magnetic resonance imaging (MRI) to scan the heart and skeletal muscles during exercises to assess blood flow, oxygenation and function.",[29,258,259],"Congenital Heart Disease","Heart Transplantation",[261,262],"Pediatric cardiology","Exercise cardiac MRI","2026-03-12",{"date":265,"type":35},"2026-03-16",{"date":267,"type":35},"2025-01-20",{"date":39,"type":22},{"name":270,"class":42},"University of Alberta",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":278,"maxAge":145,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":281,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":43},"100582744","study-of-the-efficacy-of-moderate-sedation-with-intra-nasal-dexmedetomidine-monitored-by-eeg-monitoring-100582744","NCT06867289","Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring","DINAMO","Inclusion Criteria:\n\n* Indication of DEX sedation for brain NMRI at the CHR de Metz-Thionville\n\n  * in a patient aged between 12 months and 5 years or\n  * for a patient aged between 5 and 18 whose cooperation during the examination appears compromised (previous failure, autism spectrum disorders, etc.).\n* Membership of a social security scheme\n* Free and informed consent obtained from the patient's legal guardian(s).\n\nExclusion Criteria:\n\n* Weight \\\u003C 10 kg\n* Patients with contraindications to the use of DEX\n\n  * Hypersensitivity to the active ingredient or to any of the excipients listed in the section on \"Hypersensitivity\".\n  * Advanced heart block (level 2 or 3), unless pacemaker implanted\n  * Uncontrolled hypotension\n  * Acute cerebrovascular pathologies\n* Patients with nasal obstruction\n* Parental refusal of DEX administration\n* Minors under guardianship\n* Minors under judicial sanction","1 Year",{"count":280,"type":22},50,[25],"This is a prospective, monocentric diagnostic study aiming to evaluate whether a sedation score obtained by a per-procedural electroencephalogram (EEG), the PSI score, could identify patients for whom a 2 μg\u002Fkg dose of DEX would not be sufficient for the successful performance of cerebral NMRI, and who could therefore benefit from a higher dosage of DEX (4 μg\u002Fkg).",[284,29],"Procedural Sedation and Analgesia",[286,287,288],"MRI","dexmedetomidine","EEG","2026-03-11",{"date":263,"type":35},{"date":292,"type":35},"2025-04-08",{"date":294,"type":22},"2027-04-08",{"name":296,"class":42},"Centre Hospitalier Régional Metz-Thionville",{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":18,"minAge":253,"maxAge":145,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":318,"locationsCount":43},"100473983","hiit-in-pediatric-heart-transplant-recipients-medbike-100473983","NCT05451979","HIIT in Pediatric Heart Transplant Recipients (MedBIKE™)","High Intensity Interval Training in Pediatric Heart Transplant Recipients: Evaluating a Novel Telemedicine Video Game-Linked Exercise Platform (MedBIKE™)","Inclusion Criteria:\n\n* Pediatric heart transplant recipients, at least 6-months post heart transplantation\n* Aged 10-18 years\n\nExclusion Criteria:\n\n* Non-English speaking (thus limiting communication during the MedBIKE™ sessions)\n* Home environment cannot accommodate the MedBIKE™ system (for example, space limitations)\n* History of multiorgan transplant\n* Adult unavailable to supervise the home-based exercise sessions\n* Episode of clinical antibody- or cellular-mediated rejection within 3-months of the baseline assessment\n* Previous involvement in a cardiac rehabilitation or exercise intervention program\n* Primary cardiologist has exercise restricted the participant or counsels against participation\n* Previous exercise stress test demonstrating sustained arrhythmias, ST segment elevation or depression greater than 3mm, an inappropriate rise in blood pressure (BP) (\\\u003C20 mmHg) or a systolic BP \\>200 mmHg, or symptoms of chest pain or syncope\n* Resting arterial saturation \\\u003C85% or oxygen requirements\n* Moderate ventricular systolic dysfunction (or worse) at the most recent echocardiogram\n* History of chest pain on exertion\n* Unrepaired\u002Funpalliated CHD\n* Arrhythmias in the last year (including supraventricular tachycardia, ventricular tachycardia, atrioventricular block (Mobitz II or worse))\n* New York Heart Association class II or worse symptoms\n* Active medical inter-current illness limiting ability to participate\n* Cognitive impairment limiting the communication needed for the HIIT program\n* Extracardiac or congenital abnormality limiting the participant's functional ability to exercise",{"count":109,"type":22},[25],"Heart transplantation is the long-term treatment for children and adults with advanced heart failure. Post-transplant outcomes have improved over time, such that 50% of pediatric heart transplant recipients (HTR) remain alive with a need for re-transplantation 17-years following the initial transplant. With improved short- and medium-term outcomes, focus has shifted towards optimizing long-term survival and reducing transplant-associated morbidities. This includes strategies aimed at optimizing cardiorespiratory fitness and physical activity levels.\n\nPediatric and adult HTRs have reduced exercise capacity compared with the general population. Previous groups have shown gradual improvements in heart rate response to exercise and exercise capacity in pediatric HTRs. However, after an initial improvement, exercise capacity appears to plateau, or even decline in pediatric HTRs, and remains sub-optimal compared with the general population.\n\nMost exercise interventions in HTRs to date have focused on moderate-intensity continuous exercise (MICE), with some resistance components incorporated. More recently, high-intensity interval training (HIIT), consisting of short, intense bursts of exercise with rest periods, has been explored in the adult HTR population, with findings to date suggesting that it may yield greater improvements in cardiorespiratory fitness compared with MICE. Exercise interventions, particularly HIIT interventions, have consistently shown clinically important improvements in exercise capacity in adult HTRs that are linked with improved long-term post-transplant outcomes and well-being. Unfortunately, trials of exercise interventions in pediatric HTRs remain lacking. This study team is proposing an assessment of the feasibility of a home-based HIIT exercise program using a novel telemedicine-enable video game linked customizable cycle ergometer (MedBIKE™).",[29,308],"Transplant; Failure, Heart",[310,311,312],"Cardiac rehabilitation","High Intensity Interval Training","Telemedicine",{"date":314,"type":35},"2026-03-13",{"date":316,"type":35},"2022-02-22",{"date":39,"type":22},{"name":270,"class":42},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":17,"sex":18,"minAge":173,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":43},"100535288","pediatric-normative-markerless-movement-analysis-100535288","NCT06249880","Pediatric Normative Markerless Movement Analysis","Pediatric Normative Markerless Movement Analysis Data Collection Project","Inclusion Criteria:\n\n* Age: 3-25 years of age (with 3 and 25 year olds considered for inclusion).\n* Ambulate independently and without the use of assistive devices or orthoses.\n* Willing and interested in participating.\n\nExclusion Criteria:\n\n* Neuromuscular disorders such as cerebral palsy, muscular dystrophy, myotonic dystrophy, spinal muscular atrophy, peripheral neuropathy, or other generalized muscle and\u002For nerve issues.\n* Evidence of developmental delays, muscle weakness, decreased muscle tone, joint stiffness, muscle or bone deformity.\n* Currently using or has a history of using assistive technology devices, bracing\u002Forthoses, manual or powered mobility equipment.\n* History of premature birth.\n* Currently or has a history of taking medication or pharmaceutical treatment related to musculoskeletal side-effects\u002Fscenario\u002Fdiagnosis.","25 Years",{"count":92,"type":22},"The objective of this project is to collect baseline data from a normative population of 20 children that gender and age matches the population of patients expected to be treated by Mary Bridge Children's Research \\& Movement Lab.",[29,330],"Adolescent",[332,333,334],"Motion Analysis","Kinetics","Kinematics","2026-03-05",{"date":337,"type":35},"2026-03-09",{"date":339,"type":35},"2024-03-01",{"date":341,"type":22},"2028-12",{"name":343,"class":42},"MultiCare Health System Research Institute",{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":18,"minAge":253,"maxAge":145,"enrollmentInfo":351,"targetDuration":4,"studyType":23,"phases":353,"briefSummary":354,"conditions":355,"keywords":356,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":43},"100406704","hiit-in-youth-with-congenital-heart-disease-medbike-100406704","NCT04575883","HIIT in Youth With Congenital Heart Disease (MedBIKE)","High Intensity Interval Training in Youth With Congenital Heart Disease: A Prospective Clinical Trial of a Novel Telemedicine Video Game-Linked Exercise Platform","Inclusion Criteria:\n\n* Children and adolescents aged 10-18 years\n* Repaired moderate-complex congenital heart disease\n\nExclusion Criteria:\n\n* Non-English speaking (thus limiting communication during the MedBIKE™ sessions)\n* Home environment cannot accommodate the MedBIKE™ system (space limitations)\n* Previous involvement in a cardiac rehab or exercise intervention program\n* Primary cardiologist has exercise restricted the participant or counsels against participation\n* Previous exercise stress test demonstrating sustained arrhythmias, ST segment elevation or depression greater than 3mm, an inappropriate rise in blood pressure (BP) (\\\u003C20 mmHg) or a systolic BP \\>200 mmHg, or symptoms of chest pain or syncope\n* Resting arterial saturation \\\u003C85% or oxygen requirements\n* Moderate ventricular systolic dysfunction (or worse) at the most recent echocardiogram\n* History of chest pain on exertion\n* Unrepaired\u002Funpalliated CHD\n* Arrhythmias in the last year (including supraventricular tachycardia, ventricular tachycardia, atrioventricular block (Mobitz II or worse))\n* New York Heart Association class II or worse symptoms\n* Active medical inter-current illness limiting ability to participate\n* Cognitive impairment limiting the communication needed for the HIIT program\n* Extracardiac or congenital abnormality limiting the participant's functional ability to exercise",{"count":352,"type":22},44,[25],"Congenital heart disease (CHD), the most common birth defect, is present in nearly 1% of the population. CHD patients are associated with intense resource utilization and premature death in adulthood. The risk of premature death is linked with reduced exercise capacity, a finding consistently noted in youth with CHD. Reduced exercise capacity in this population has also been associated with reduce physical activity and health-related quality of life.\n\nCardiac rehabilitation (CR) in adults with acquired heart disease is an established secondary prevention strategy that improves exercise capacity. The investigators propose a prospective clinical trial of a home-based high intensity interval training (HIIT) program using a novel telemedicine-equipped video game-linked cycle ergometer (MedBIKE™) for 10 to 18 year olds with repaired moderate-complex CHD. The pilot study with the MedBIKE has shown promising results. The investigators now seek to study the efficacy of this program in a broader CHD population.",[258,29],[310,311,312],"2026-02-04",{"date":359,"type":35},"2026-02-05",{"date":361,"type":35},"2022-11-22",{"date":363,"type":22},"2026-12-31",{"name":270,"class":42},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":18,"minAge":372,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":375,"conditions":376,"keywords":377,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":43},"100322743","pharmacokinetics-of-drugs-administered-to-children-100322743","NCT03481881","Pharmacokinetics of Drugs Administered to Children","Pharmacokinetics of Drugs Administered to Children Per Standard of Care","Inclusion Criteria:\n\n* Children (\\\u003C 21 years of age) who are receiving understudied drugs of interest per standard of care as prescribed by their treating caregiver\n\nExclusion Criteria:\n\n* Failure to obtain consent\u002Fassent (as indicated)","0 Years","20 Years",{"count":230,"type":22},"This is a prospective study of children \\\u003C21 years of age with the goal of characterizing the PK of drugs administered per standard of care as prescribed by the treating caregiver.",[29],[378],"pharmacokinetics","2026-01-05",{"date":381,"type":35},"2026-01-07",{"date":383,"type":35},"2013-08-14",{"date":385,"type":22},"2033-08-14",{"name":387,"class":42},"Duke University",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":414},"100555183","long-term-follow-up-of-patients-treated-with-miltenyi-cell-and-gene-therapies-100555183","NCT06508775","Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies","LONGSAFE","Inclusion Criteria:\n\n* Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.\n* Patient has provided informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* No exclusion criteria",{"count":92,"type":22},[25],"The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.",[399,400,29,401,402,403,404],"Melanoma Stage III","B-cell Non Hodgkin Lymphoma","Childhood Non-Hodgkin Lymphoma","Acute Lymphatic Leukemia","Chronic Lymphatic Leukemia","Melanoma Stage IV","2025-11-20",{"date":407,"type":35},"2025-11-26",{"date":409,"type":35},"2024-05-05",{"date":411,"type":22},"2040-12-31",{"name":413,"class":82},"Miltenyi Biomedicine GmbH",7,{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":18,"minAge":422,"maxAge":52,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":430,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":43},"100539426","vr-pat-and-fnirs-to-identify-cns-biomarkers-of-pain-100539426","NCT06303687","VR-PAT and fNIRS to Identify CNS Biomarkers of Pain","Imaging Pain in a Virtual World: Neuroimaging Biomarkers for Assessing Brain Mechanisms Mediating Virtual Reality Pain Management in Children","Inclusion Criteria:\n\n1. Being treated for acute burn injury\n2. Age 6-17 years, inclusive\n3. Admitted to NCH burn unit for treatment\n4. Have a dressing that requires daily changes over 3 days\n5. Patient and family caregivers can communicate (read and write) using English\n\nExclusion Criteria:\n\n1. Any wounds that may interfere with study procedures\n2. Vision, hearing, or cognitive\u002Fmotor impairments preventing valid administration of study measures\n3. History of motion sickness, seizure disorder, dizziness, or migraine headaches precipitated by visual auras\n4. Minors in foster care, prisoners, or currently pregnant\n5. Suspected child abuse\n6. Unable to communicate in English","6 Years",{"count":165,"type":22},[25],"This study aims to use functional near-infrared spectroscopy (fNIRS) to identify and quantify pain biomarkers during burn dressing changes and pain relief induced by virtual reality (VR).",[427,29,428,429],"Acute Pain","Procedural Pain","Burns",[431,432,433,434,435,436],"Virtual Reality","VR","fNIRS","Pain","Biomarker","Neuroimaging","2025-11-19",{"date":439,"type":35},"2025-11-24",{"date":441,"type":22},"2026-07",{"date":443,"type":22},"2026-12",{"name":445,"class":42},"Nationwide Children's Hospital",{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":17,"sex":18,"minAge":372,"maxAge":326,"enrollmentInfo":454,"targetDuration":456,"studyType":93,"phases":4,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":43},"100467071","pediatric-orthopaedic-implant-safety--efficacy-100467071","NCT05361980","Pediatric Orthopaedic Implant Safety & Efficacy","Global Pediatric Orthopaedic Implant Safety & Efficacy Clinical Follow-up Program","Global POISE","Inclusion Criteria:\n\n* Patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU. Off-label use is strongly discouraged; however, any and all on- and off-label indications for use of the products in this program will be collected and stratified accordingly\n* Patients must be able to adhere to the required length of follow-up for the endpoints of each individual product\n* Informed consent\u002Fassent is required\n\nExclusion Criteria:\n\n* Patients with a demonstrated sensitivity to metals\n* Patients with an inability to follow a post-operative regimen",{"count":455,"type":22},4000,"2 Years","Implant devices are important tools - their use is essential across a number of orthopaedic indications, including hip conditions, trauma and limb deformity.\n\nGiven the vital role fixation devices play in maintaining alignment, promoting healthy bone healing and preventing joint degeneration, it is essential to understand the expected lifetime outcomes of these implants, and evaluate their safety and efficacy.\n\nProspective implant efficacy and safety registries are needed to support this endeavour, especially considering new regulatory requirements from the European Union Medical Devices Regulation (EU MDR) in relation to post-market clinical follow-up (PMCF).",[459,460,461,462,463,464,465,466,29,467,468],"Fracture","Lengthening; Leg","Orthopedic Disorder","Deformity of Limb","Deformity; Bone","Implant Breakage","Implant Complication","Hip Dysplasia","Hip Disease","Hip Dislocation",{"date":439,"type":35},{"date":471,"type":35},"2022-01-06",{"date":473,"type":22},"2029-12",{"name":475,"class":42},"University of British Columbia",{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":373,"enrollmentInfo":483,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":43},"100544364","multicenter-study-on-rehabilitation-medical-data-for-pediatric-big-brain-development-100544364","NCT06367920","Multicenter Study on Rehabilitation Medical Data for Pediatric Big Brain Development","Multicenter Study on Rehabilitation Medical Data for Pediatric Big Brain","Inclusion Criteria:\n\n* Healthy subjects and patients 20 years old or younger who underwent imaging examinations performed at the Department of Rehabilitation Medicine at our hospital from January 2010 to December 2023 (patients who underwent brain MRI tests to determine the cause of developmental delay)\n\nExclusion Criteria:\n\n* None",{"count":484,"type":22},2000,"Retrospective study for development of imaging-genetics (brain imaging\u002Fgenome big data) models and algorithms that are clinically explainable and have high predictive performance in brain research on pediatric developmental disorders",[29,487],"Healthy","2025-09-15",{"date":490,"type":35},"2025-09-17",{"date":492,"type":35},"2023-03-23",{"date":363,"type":22},{"name":495,"class":42},"Bundang CHA Hospital",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":18,"minAge":503,"maxAge":145,"enrollmentInfo":504,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":506,"conditions":507,"keywords":509,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":517,"locationsCount":519},"100556781","evaluating-the-relationship-between-skin-color-and-pulse-oximeter-accuracy-in-children-100556781","NCT06529575","Evaluating the Relationship Between Skin Color and Pulse Oximeter Accuracy in Children","PACH","Inclusion Criteria:\n\n* Child is between 1 month and 18 years old\n* Child is undergoing a cardiac catheterization procedure that typically involves direct arterial oxygen saturation measurement by co-oximeter from a location reflective of systemic saturation.\n\nExclusion Criteria:\n\n* Child previously participated in the study\n* Child has differential cyanosis across extremities\n* Child is receiving an intravenous vasoconstrictor prior to procedure\n* Child has a ventricular assist device (VAD)","4 Weeks",{"count":505,"type":22},650,"This multisite study seeks to understand whether and how pulse oximeter accuracy varies across children with different skin colors in real world clinical settings. Many factors can affect how well pulse oximeters work; for example, movement and even fingernail polish. Some studies in adults show that skin color may also affect the pulse oximeter reading. In this study, we will explore pulse oximeter accuracy in children of all skin colors who are undergoing cardiac catheterizations. The study will address limitations of prior work by objectively measuring skin color across multiple dimensions of color and comparing the the pulse oximeter reading to the \"gold standard\" blood sample measurement.",[29,508],"Cardiac Defect",[510],"Pulse Oximetry","2025-09-05",{"date":513,"type":35},"2025-09-12",{"date":515,"type":35},"2024-08-14",{"date":341,"type":22},{"name":518,"class":42},"University of Pennsylvania",3,{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":17,"sex":18,"minAge":145,"maxAge":528,"enrollmentInfo":529,"targetDuration":4,"studyType":23,"phases":531,"briefSummary":532,"conditions":533,"keywords":536,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":43},"100398167","impact-of-a-mhealth-supportive-tool-on-cardiopulmonary-resuscitation-situational-awareness-100398167","NCT04464603","Impact of a mHealth Supportive Tool on Cardiopulmonary Resuscitation' Situational Awareness","Impact of a Shared Decision-making mHealth Tool on Caregivers' Team Situational Awareness, Communication Effectiveness, and Performance During Pediatric Cardiopulmonary Resuscitation: a Randomized Controlled Trial","InterFACE","Inclusion Criteria:\n\n* Any physician performing a fellowship in the pediatric emergency department.\n* Any postgraduate residents pursuing a \\\u003C5 years residency in pediatrics.\n* To be registered nurses from the PED.\n* To have previously completed a standardized 15-min introductory course on the use of the InterFACE tool dispensed by the study investigators.\n* Participation agreement\n\nExclusion Criteria:\n\n* To have not undergone the standardized 15-min introductory course on the use of the InterFACE tool dispensed by the study investigators.\n* Participation to a simulation in the past month is an exclusion criterion to avoid a recent training effect.","65 Years",{"count":530,"type":22},36,[25],"This study will be a prospective, single-center, randomized controlled trial in a tertiary pediatric emergency department with two parallel groups of voluntary pediatric physicians and nurses. The impact of a mHealth supportive tool will be compared with conventional communication methods on situational awareness, leadership, team communication effectiveness and performance during standardized, simulation-based, pediatric in-hospital cardiac arrest scenario using a high-fidelity manikin. Thirty-six participants will be randomized (1:1). The primary endpoint is the situational awareness score measured with the situation awareness global assessment technique (SAGAT) instrument.",[534,29,535],"Cardiopulmonary Arrest","Resuscitation",[537,538,539,540,541,542],"Information technologies","Situation Awareness","Teamwork","Leadership","Mobile applications","Biomedical Technology","2025-08-17",{"date":545,"type":35},"2025-08-19",{"date":547,"type":22},"2025-11-01",{"date":549,"type":22},"2026-01-31",{"name":551,"class":42},"Pediatric Clinical Research Platform",{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":559,"enrollmentInfo":560,"targetDuration":4,"studyType":23,"phases":562,"briefSummary":563,"conditions":564,"keywords":4,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":574,"locationsCount":43},"100597525","femoral-arterial-cannulation-in-pediatrics-100597525","NCT07059624","Femoral Arterial Cannulation in Pediatrics","Femoral Arterial Cannulation Performed by Anesthesia Residents: A Comparison Between Ultrasound-Guided \"Modified Dynamic Needle Tip Positioning, Short-Axis, Out-Of-Plane\" and \"Conventional, Short-Axis, Out-Of-Plane\" Methods","Inclusion Criteria:\n\n* Infants and children under 12 years of age.\n* American Society of Anesthesiologist (ASA) physical status II-IV.\n* Patients with congenital heart disease undergoing cardiac surgery who do not have existing arterial line access.\n\nExclusion Criteria:\n\n* Need for emergency surgery.\n* Hemodynamic instability.","12 Years",{"count":561,"type":22},80,[25],"The goal of this clinical trial\\] is to evaluate the efficacy and safety of the ultrasound-guided \"Modified Dynamic\n\nNeedle Tip Positioning Short-Axis, Out-Of-Plane\" (MDNTP-SAOP) technique compared to the \"Conventional, Short-Axis, Out-Of-Plane\" (C-SAOP) technique for femoral arterial cannulation performed by anesthesia residents in children. The main question it aims to answer is:\n\nWhat is the time required for attempted femoral arterial cannulation by anesthesia residents at the first puncture site?\n\nResearchers will compare the efficacy and safety of MDNTP-SAOP versus C-SAOP methods for femoral arterial cannulation performed by anesthesia residents in infants and children undergoing cardiac surgery.\n\nParticipants will be randomized to either the MDNTP-SAOP or the C-SAOP group. Intraoperatively, time taken for attempted cannulation by the resident at the first site of femoral arterial puncture, number of attempts at arterial cannulation, and number of cannulae required for successful cannula insertion will be recorded. Adverse events will be monitored on postoperative days 1 and 3. The insertion site will be examined for thrombosis, hematoma, infection, or limb ischemia distal to the insertion site",[29,565,566],"Cardiac Complication","Anesthesia","2025-07-18",{"date":569,"type":35},"2025-07-20",{"date":571,"type":35},"2025-07-09",{"date":573,"type":22},"2027-01-01",{"name":575,"class":42},"American University of Beirut Medical Center",{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":17,"sex":18,"minAge":228,"maxAge":583,"enrollmentInfo":584,"targetDuration":4,"studyType":23,"phases":586,"briefSummary":587,"conditions":588,"keywords":591,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":43},"100595417","the-effect-of-non-pharmacological-methods-on-pain-fear-100595417","NCT07032181","The Effect of Non-pharmacological Methods on Pain, Fear","The Effect of Virtual Reality and Guided Imagery Method Used During Blood Sampling on Pain, Fear","Inclusion Criteria:\n\n* The child must be between 8 and 14 years old.\n* Both the child and the parent must volunteer to participate in the study.\n* The child and the parent must speak Turkish at a native level.\n* The child must not have taken any medication with analgesic, antipyretic, or anti-inflammatory effects within the last 6 hours\n\nExclusion Criteria:\n\n* The child has visual, hearing, or speech impairments.\n* The child is illiterate.\n* The child has a clinical condition that prevents the use of VR glasses or headphones.\n* The child has an allergy to strawberries (mentioned in the guided imagery script) or a fear of forests or squirrels.\n* The child has a disease that may cause chronic pain.\n* The child has any auditory, mental, or neurological disability that could affect participation in the study","14 Years",{"count":585,"type":22},93,[25],"This randomized controlled experimental study aims to evaluate the effectiveness of guided imagery and virtual reality (VR) in reducing pain and fear in children during blood draw procedures. The sample will consist of children aged 8-14 who meet the inclusion criteria and present to the Koç Hospital Pediatric Clinic Blood Drawing Room. After informing the children and their parents about the study, written and verbal consents will be obtained. Participants will then be randomly assigned into one of three groups-two experimental (guided imagery and VR) and one control-using a random number list generated via Excel.\n\nPre-procedure: Prior to the intervention, children and parents will be informed using consent forms. Demographic and baseline data will be collected using the Child Patient Introductory Information Form. Pain will be assessed with the Faces Pain Scale-Revised (FPS-R) by the child and the Visual Analog Scale (VAS) by the parent and observer. Fear will be evaluated using the Children's Fear Scale (CFS), self-rated by the child and assessed by the parent\u002Fobserver. A pulse oximeter will be attached to measure baseline pulse and oxygen saturation (SpO2) levels starting 1 minute before the procedure.\n\nGuided Imagery Group: Children will listen to an audio recording titled \"A Walk in the Forest\" using headphones. They will be instructed to close their eyes and imagine the scene described, focusing on the sound to facilitate distraction. The audio will start 1 minute prior to the procedure.\n\nVirtual Reality Group: Children in this group will wear VR glasses and watch an immersive AI-generated video of \"A Walk in the Forest.\" This aims to provide a more interactive distraction during the blood draw.\n\nControl Group: Children will undergo routine blood draw procedures with no additional distraction techniques. The procedure will be explained as usual.\n\nProcedure: A trained nurse will perform all blood draws. During the procedure, SpO2 and pulse data will be recorded. Post-procedure, these will also be documented immediately and 1 minute after the intervention.\n\nPost-procedure: After the procedure, FPS-R and CFS will be used again by children to assess pain and fear. Parents and observers will complete VAS and CFS to evaluate observed pain and fear. Headphones or VR glasses will be removed following the final measurement.",[589,434,590,29],"Children","Fear",[73,434,590,589,592],"Blood Sampling","2025-06-13",{"date":595,"type":35},"2025-06-22",{"date":597,"type":22},"2025-09-10",{"date":599,"type":22},"2026-09-14",{"name":601,"class":42},"Fenerbahce University",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":18,"minAge":90,"maxAge":608,"enrollmentInfo":609,"targetDuration":4,"studyType":23,"phases":611,"briefSummary":612,"conditions":613,"keywords":614,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":43},"100354720","umbilical-vessel-catheterization-under-ecg-monitoring-and-guidance-100354720","NCT03898596","Umbilical Vessel Catheterization Under ECG Monitoring and Guidance","Inclusion Criteria:\n\n* Neonate pediatric patient\n* 2 - 6kg\n* Require or currently have UVC\n\nExclusion Criteria:\n\n* Participants who do not consent or have parental consent\n* Patients who are clinically unstable","45 Days",{"count":610,"type":22},150,[25],"Umbilical venous catheters (UVC) are typically places with poor guidance and some radiological confirmation. Misplacement of the catheter could lead to its placement in other unintended anatomical areas such as the liver or the spleen, which could be detrimental in critically-ill infants. Our study aims at using a more non-invasive means of placing and continuously monitoring catheter placement using superficial electrocardiogram (ECG) tracings.",[29],[615,616,617],"Neonates","Electrocardiogram","Umbilical Vein Catheterization","2025-04-30",{"date":620,"type":35},"2025-05-01",{"date":622,"type":35},"2020-08-25",{"date":624,"type":22},"2025-12",{"name":626,"class":42},"Stanford University",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":18,"minAge":635,"maxAge":145,"enrollmentInfo":636,"targetDuration":559,"studyType":93,"phases":4,"briefSummary":638,"conditions":639,"keywords":641,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":414},"100588177","dutch-registry-of-pediatric-cardiac-arrest-100588177","NCT06938009","Dutch Registry of Pediatric Cardiac Arrest","Pediatric Resuscitation Neuroprognostication and Outcomes Registry","PROGNOSE","Inclusion Criteria:\n\n* Pediatric patients under the age of 18\n* Experienced in-hospital or out-of-hospital cardiac arrest in the Netherlands\n* Attended by emergency medical services or admitted to one of the seven participating Dutch academic pediatric hospitals\n* Cardiac arrest defined as absence of palpable pulse or need for chest compressions lasting ≥1 minute\n* Arrest managed under European Resuscitation Council guidelines (BLS\u002FAPLS)\n\nExclusion Criteria:\n\n* Cardiac arrest occurring in neonates younger than 24 hours of age\n* Cardiac arrest occurring in a neonatal intensive care unit (NICU) setting","24 Hours",{"count":637,"type":22},500,"The goal of this observational study is to understand the long-term outcomes of children in the Netherlands who experience cardiac arrest, either in or outside of the hospital. The main questions it aims to answer are:\n\nWhat are the survival rates and neurological outcomes in children after cardiac arrest?\n\nWhat types of emergency and post-resuscitation care are provided, and how do they impact long-term recovery?\n\nHow do children and their families function over time after the event?\n\nResearchers will analyze data from routine medical records and follow patients through standard outpatient visits. No extra procedures will be required beyond normal care. For those who survive to hospital discharge, additional follow-up data will be collected with consent.\n\nParticipants will:\n\nBe children under 18 years old who have had a cardiac arrest and were treated in one of the seven participating academic hospitals\n\nHave their routine medical care data collected anonymously\n\nBe invited (if surviving) for follow-up visits at 3, 12, and 24 months post-arrest and at specific ages (5, 8, 12, and 17 years) to assess physical and psychological recovery",[640,29],"Cardiac Arrest (CA)",[642,643,644,645],"Pediatric cardiac arrest","Neuroprognostication","Long-term outcomes","Observational registry","2025-04-14",{"date":648,"type":35},"2025-04-22",{"date":650,"type":35},"2023-06-14",{"date":652,"type":22},"2030-01",{"name":654,"class":42},"Matthijs de Hoog",{"id":656,"slug":657,"hasResults":12,"nctId":658,"briefTitle":659,"officialTitle":660,"acronym":661,"eligibilityCriteria":662,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":663,"enrollmentInfo":664,"targetDuration":666,"studyType":93,"phases":4,"briefSummary":667,"conditions":668,"keywords":672,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":682,"locationsCount":165},"100528894","current-practice-of-ventilation-strategies-in-children-undergoing-general-anesthesia-100528894","NCT06166706","Current Practice of Ventilation Strategies in Children Undergoing General Anesthesia","Current Practice of Ventilation Strategies in Children Undergoing General Anesthesia and Associations With Postoperative Pulmonary Complications - a Multicenter Prospective Cohort Study","BIG APPLE","Inclusion Criteria:\n\n* aged ≤ 16 years;\n* undergoing general anesthesia\n* airway management with tube or LMA; and\n* connected to mechanical ventilator . minimum duration of procedure: 15 minutes\n\nExclusion Criteria:\n\n* patients undergoing surgical procedures involving extra-corporal circulation;\n* patients receiving ventilation with high frequency jet ventilation or high frequency oscillatory ventilation;\n* sedation without airway management in the form of a endotracheal tube or a supraglottic airway device; and\n* (rigid) bronchoscopic procedures with maintenance of spontaneous ventilation.","16 Years",{"count":665,"type":22},10000,"5 Days","Postoperative pulmonary complications (PPCs) are common in children undergoing general anesthesia and are associated with prolonged stay in the hospital and high costs. Development of PPCs is associated with ventilator settings in adult patients undergoing general anesthesia. Data on perioperative ventilator settings in children are lacking, leaving the anaesthetist without guidance. Consequently, the current standard of care in perioperative mechanical ventilation in children is expected to be extremely heterogeneous, leading to ventilation with higher levels of energy than necessary. Therefore, it is highly necessary to evaluate the current practice in perioperative ventilation in children and to determine associations with PPCs.",[669,29,670,671],"Mechanical Ventilation Complication","Pulmonary Complication","Perioperative\u002FPostoperative Complications",[673,674,675],"pediatric anesthesia","postoperative pulmonary complications","mechanical ventilation","2025-04-07",{"date":678,"type":35},"2025-04-09",{"date":680,"type":35},"2024-01-29",{"date":381,"type":22},{"name":683,"class":42},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]